<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Filana Therapeutics, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/filana-therapeutics-inc</link>
    <description>Latest news and press releases for Filana Therapeutics, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 15 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/filana-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7527c51cc36e475335da5.webp</url>
      <title>Filana Therapeutics, Inc.</title>
      <link>https://6ix.com/company/filana-therapeutics-inc</link>
    </image>
    <item>
      <title>Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data</title>
      <link>https://6ix.com/company/filana-therapeutics-inc/news/filana-therapeutics-announces-publication-in-epilepsia-of-preclinical-simufilam-data</link>
      <guid isPermaLink="true">https://6ix.com/company/filana-therapeutics-inc/news/filana-therapeutics-announces-publication-in-epilepsia-of-preclinical-simufilam-data</guid>
      <pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
      <description>Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend previously published preclinical findingsTSC-related epilepsy affects approximately 45,000 people in the U.S. AUSTIN, Texas, April 15, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing therapies for Tubero</description>
    </item>
    <item>
      <title>Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/filana-therapeutics-inc/news/filana-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-2</link>
      <guid isPermaLink="true">https://6ix.com/company/filana-therapeutics-inc/news/filana-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-2</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
      <description>Working to advance TSC-related epilepsy program, with a focus on capital efficiencyAUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dy</description>
    </item>
  </channel>
</rss>